+

WO2008152654A1 - Protéines hybrides du charbon, compositions et leurs applications - Google Patents

Protéines hybrides du charbon, compositions et leurs applications Download PDF

Info

Publication number
WO2008152654A1
WO2008152654A1 PCT/IN2008/000368 IN2008000368W WO2008152654A1 WO 2008152654 A1 WO2008152654 A1 WO 2008152654A1 IN 2008000368 W IN2008000368 W IN 2008000368W WO 2008152654 A1 WO2008152654 A1 WO 2008152654A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
anthrax
fusion proteins
recombinant fusion
optionally
Prior art date
Application number
PCT/IN2008/000368
Other languages
English (en)
Inventor
Rajesh Jain
Anil Kumar Chawla
Original Assignee
Panacea Biotec Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Limited filed Critical Panacea Biotec Limited
Publication of WO2008152654A1 publication Critical patent/WO2008152654A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Definitions

  • the present invention relates to anthrax recombinant fusion proteins, process of preparation of such proteins and compositions thereof.
  • the recombinant fusion proteins of the present invention comprise the Edema factor protein and the Lethal factor protein (LF) optionally with a linker.
  • the recombinant fusion proteins of the present invention comprise truncated Edema factor protein and truncated Lethal factor protein (LF) optionally with a linker.
  • nucleic acids encoding the fusion proteins of the present invention.
  • the present invention provides a composition against an infection of B.
  • anthracis comprising the anthrax recombinant fusion protein mixed with a native or mature or mutated PA, and optionally with one or more suitable adjuvant(s) or excipients or both.
  • the present invention relates to process of preparation of anthrax recombinant fusion proteins, native or mature or mutated PA, compositions comprising said recombinant fusion proteins optionally mixed with native or mature or mutated PA and methods of using them.
  • the compositions of the present invention may be useful as a pre-exposure and post-exposure prophylactic and/or therapeutic vaccine against anthrax.
  • Anthrax is an infectious bacterial disease caused by Bacillus anthracis. It occurs most commonly in wild and domestic herbivores (sheep, goats, camels, antelope, cattle, etc.) but may also occur in humans. Infection can occur by cutaneous exposure, by ingestion (gastrointestinal anthrax), or by inhalation (pulmonary anthrax). 95% of anthrax infections in humans occur by cutaneous infection, either from contact with unvaccinated, infected animals in an agricultural setting, or by handling contaminated animal products (meat, leather, hides, hair, wool, etc.) in an industrial setting. Cutaneous anthrax is fatal in about 20% of cases if untreated, but it can usually be overcome with appropriate antimicrobial therapy.
  • Inhalation or gastrointestinal anthrax infection is much more serious and much more difficult to treat. Inhalation anthrax results in respiratory shock and is fatal in 90%- 100% of cases; gastrointestinal anthrax results in severe fever, nausea and vomiting, resulting in death in 25%-75% of cases.
  • An effective vaccine against pre-exposure prophylactic to anthrax was developed in United States in the 1950s and 1960s, and a vaccine was approved by FDA in 1970.
  • Anthrax vaccine Anthrax Vaccine Adsorbed (or AVA, commercial name BioThrax”)
  • AVA aluminum hydroxide
  • benzethonium chloride added.
  • the ability of the vaccine to elicit an immune response in humans is well- documented.
  • the course of vaccination consists of six subcutaneous injections of 0.5 mL doses of vaccine over eighteen months, with annual boosters to maintain immunity. This vaccination is believed to provide immunity that is 90%- 100% effective against aerosol anthrax challenge, based on animal studies and incidental human data.
  • Anthrax a potentially fatal disease, is caused by Bacillus anthracis.
  • the virulence of this pathogen is mediated by a capsule of a poly-D-[small gamma, Greek] -glutamic acid and an exotoxin composed of three proteins.
  • the three protein components are the protective antigen (PA, 83 KDa), lethal factor (LF, 90.2 KDa) and edema factor (EF, 88.8 KDa) encoded by genes pag, lef, cya respectively in pXOl plasmids.
  • PA protective antigen
  • LF lethal factor
  • EF 88.8 KDa
  • LT lethal toxins
  • ET edema toxins
  • Plasmid pXOl and pXO2 encodes the three toxin components and enzymes for capsule biosynthesis, respectively.
  • the genes coding for these three protein components and the capsule are found in the endogenous plasmids pXOl and pXO2, respectively.
  • the capsule of Bacillus anthracis composed of poly-D-glutamic acid, serves as one of the principal virulence factors during anthrax infection. By virtue of its negative charge, the capsule is purported to inhibit host defence through inhibition of phagocytosis of the vegetative cells by macrophages.
  • the capsule In conjunction with lethal factor (LF) and edema factor (EF), whose target cells include macrophages and neutrophils, respectively, the capsule allows virulent anthrax bacilli to grow virtually unimpeded in the infected host. Spores germinating in the presence of serum and elevated CO[sub]2 release capsule through openings on the spore surface in the form of blebs which may coalesce before sloughing of exosporium and outgrowth of fully encapsulated vegetative cell.
  • LF lethal factor
  • EF edema factor
  • US patent no. 5,591,631 discloses a nucleic acid encoding a fusion protein, comprising a nucleotide sequence encoding the protective antigen (PA) binding domain of the native lethal factor (LF) protein and a nucleotide sequence encoding a polypeptide, wherein said fusion protein lacks the catalytic domain of LF.
  • PA protective antigen
  • LF native lethal factor
  • US patent no. 5,677,274 describes a method for targeting compounds having a desired biological activity not present on native anthrax lethal factor (LF) to a specific cell population, comprising: a) administering to the cell population a first compound comprising a first protein consisting essentially of: i) the translocation domain and the anthrax lethal factor (LF) binding domain of the native anthrax protective antigen (PA) protein, and ii) a ligand domain that specifically binds the first protein to a target on the surface of the cell population to bind the first compound to said surface; and b) administering to the resultant cell population a second compound comprising a fusion protein or conjugate consisting essentially of: i) the anthrax protective antigen (PA) binding domain of the native anthrax lethal factor (LF) protein, chemically attached to ii) a biological activity-inducing polypeptide to bind the second compound to the first compound on the surface of the cell population, internalize the second compound into the cell population, and
  • US publication no. 20040028695 describes an immunogenic composition to prepare a vaccine against a lethal infection of B. anthracis in an animal comprising an effective immunizing amount of at least one recombinant B. anthracis PA (rPA) protein and at least one recombinant B. anthracis LF (rLF) protein.
  • rPA B. anthracis PA
  • rLF recombinant B. anthracis LF
  • PCT publication no. WO2003048390 describes a recombinant DNA Construct comprising an expression vector and a DNA fragment including genes for wild type Protective Antigen (PA) or wild type Lethal Factor (LF) or wild type Edema Factor (EF).
  • PA Protective Antigen
  • LF wild type Lethal Factor
  • EF Edema Factor
  • PCT publication no. WO2003040179 discloses a process for preparing anthrax protective antigen protein from E.coli using fed batch culture technique.
  • PCT publication no. WO200337370 discloses an antigenic pharmaceutical composition
  • an antigenic pharmaceutical composition comprising Protective Antigen (PA) and Lethal Factor (LF), wherein said PA and/or LF lacks a functional binding site, thereby preventing said PA and LF from binding together via said binding site or thereby preventing said PA from binding to a native PA cell receptor via said binding site, and wherein said composition is substantially non-toxic to animal cells.
  • PA Protective Antigen
  • LF Lethal Factor
  • PCT publication no. WO2002100340 describes an immunogenic composition capable of raising an anti-5. anthracis antigen immune response in a mammal consisting essentially of recombinant B. anthracis Protective Antigen (rPA).
  • rPA anthracis Protective Antigen
  • the present invention not only provides a cost-effective method to develop safe and effective vaccine against anthrax but also attempts to provide a single vaccine composition that may be useful both as a pre-exposure and post-exposure prophylactic and/or as a therapeutic product.
  • anthrax recombinant fusion proteins comprising a native Edema factor protein or mutated Edema factor protein or truncated Edema factor protein, and a native Lethal factor protein or mutated Lethal factor protein or truncated Lethal factor protein optionally with a linker.
  • anthrax recombinant fusion proteins comprising a truncated Edema factor protein (EFn) and a truncated Lethal factor protein (LFn) optionally with a linker.
  • EFn Edema factor protein
  • LFn truncated Lethal factor protein
  • anthrax recombinant fusion proteins comprising a truncated Edema factor protein (SEQ. ID No. 2) and a truncated Lethal factor protein (SEQ. ID No. 1) optionally with a linker.
  • It is another objective of the present invention to provide an immunogenic composition comprising anthrax recombinant fusion proteins comprising edema factor protein and lethal factor protein optionally with a linker.
  • composition against an infection of B. anthracis which comprises anthrax recombinant fusion proteins comprising EFn protein and LFn protein optionally with a linker, mixed with a native or mature or mutated PA, and optionally with one or more suitable adjuvant(s).
  • an immunogenic prophylactic or a therapeutic composition useful against an infection of B. anthracis in a subject which comprises administration of an effective amount of anthrax recombinant fusion proteins comprising EFn protein and LFn protein optionally with a linker, mixed with a native or mature or mutated PA and optionally one or more adjuvant(s) to the said subject.
  • It is another objective of the invention to provide an immunogenic composition comprising anthrax recombinant fusion protein comprising truncated edema factor protein (SEQ. ID. No. 2) and truncated lethal factor protein (SEQ. ID No. 1) optionally with a linker.
  • anthrax recombinant fusion protein comprising truncated edema factor protein (SEQ. ID. No. 2) and truncated lethal factor protein (SEQ. ID No. 1) optionally with a linker.
  • anthracis comprising anthrax recombinant fusion proteins comprising truncated Edema factor protein (SEQ ID No. 2) and truncated Lethal factor protein (SEQ ID No. 1) mixed with a native or mutated or mature Protective Antigen (PA) optionally with a linker and one or more pharmaceutically acceptable adjuvant(s).
  • PA Protective Antigen
  • an immunogenic composition comprising anthrax recombinant fusion proteins selected from amino acid sequence set forth in SEQ ID No. 3 or SEQ ID No. 4 optionally with one or more pharmaceutically acceptable adjuvant(s).
  • Anthracis in a subject which comprises administration of an effective amount of anthrax recombinant fusion proteins comprising EFn protein and LFn protein optionally with a linker which is one or more amino acid residues, mixed with a native or mature or mutated PA, and optionally one or more adjuvant(s) to the said subject.
  • compositions which are potentially immunogenic but safe.
  • compositions are useful as a prophylactic and/or a therapeutic vaccine against anthrax.
  • FIG. 2 Schematic representation of recombinant expression plasmid "pPAK- NATPRO"
  • Figure-3 shows a codon optimized Sequence of PA.
  • Figure-4 shows a Protein Sequence of PA.
  • Figure-5 shows a LFn with Glycine as linker Recombinant Construct in pET28a, wherein clone LFn has been constructed for the expression of LFn in E.coli BL21(DE3).
  • the genes were amplified from the pXOl region of the B. anthracis using specific primers and inserted in pET-28a expression vector having Kanamycin as selection marker.
  • the recombinant plasmid was then transformed into E.coli BL21 (DE3) cells for the expression of protein.
  • Figure-6 shows a Nucleotide Sequence of truncated LF.
  • Figure 7 shows a Protein Sequence of truncated LF (SEQ. ID No. 1).
  • Figure-8 shows an EFn Recombinant Construct in pET28a, wherein clone EFn has been constructed for the expression of LFn in E.coli BL21(DE3).
  • the genes were amplified from the pXOl region of the B. anthracis using specific primers and inserted in pET-28a expression vector having Kanamycin as selection marker.
  • the recombinant plasmid was then transformed into E.coli BL21 (DE3) cells for the expression of protein
  • Figure-9 shows a Nucleotide Sequence of truncated EF.
  • Figure-10 shows a Protein Sequence of truncated EF (SEQ. ID No. 2).
  • Figure- 11 shows an EFn+LFn with glycine as linker Fusion Construct.
  • Figure- 12 shows an EFn with LFn with Glycine as tail Fusion Construct pET28a (EFn+LFn) (SEQ. ID No. 3).
  • Figure- 13 shows the Primers for EFn with LFn as tail Fusion Construct.
  • Figure- 17 shows EFn+LFn as linker Fusion Construct.
  • Figure-18 shows EFn+LFn as linker Fusion Construct pET28a (EFn+LFn) (SEQ. ID NO: 1
  • Figure- 19 shows Primers for EFn with LFn as tail Fusion Construct.
  • the present invention provides anthrax recombinant fusion proteins and nucleic acids encoding the anthrax recombinant fusion proteins.
  • the present invention provides anthrax recombinant fusion proteins comprising Edema factor protein and Lethal factor protein optionally with a linker.
  • the present invention provides anthrax recombinant fusion proteins comprising a truncated Edema factor protein (EFn) and a truncated Lethal factor protein (LFn) optionally with a linker.
  • EFn truncated Edema factor protein
  • LFn truncated Lethal factor protein
  • the present invention provides anthrax recombinant fusion proteins comprising EFn protein and LFn protein optionally with one or more other linker(s) such as one or more amino acid residues, mixed with a native or mature or mutated PA.
  • the anthrax recombinant fusion proteins optionally mixed with a native or mature or mutated PA results in faster immune responses by targeting all three toxin proteins.
  • PA Protective Antigen
  • LF Lethal Factor
  • EF Esdema Factor
  • the present invention provides a composition against an infection of B. anthracis which comprises anthrax recombinant fusion proteins comprising EFn and LFn optionally with a linker, and optionally with one or more suitable adjuvant(s).
  • a pre-exposure and post exposure prophylactic and/or a therapeutic composition useful against an infection of B. anthracis in a subject which comprises administration of an effective amount of anthrax recombinant fusion proteins comprising EFn and LFn optionally with a linker, mixed with a native or mature or mutated PA and optionally one or more adjuvant(s) to said subject.
  • the present invention also provides a DNA construct comprising an expression vector and a DNA fragment comprising nucleic acids encoding the anthrax recombinant fusion proteins such that the expression vector when incorporated into a suitable host allows expression of anthrax recombinant fusion proteins.
  • a vaccine composition which is potentially immunogenic and safe. Particularly the compositions are useful as a pre-exposure and post exposure prophylactic and/or a therapeutic vaccine against anthrax.
  • the present invention provides nucleic acids encoding the DNA construct.
  • plasmids and primers and the nucleic acids encoding them which are useful in making a DNA construct for the expression of the anthrax recombinant fusion proteins.
  • the anthrax recombinant fusion proteins comprising EFn and LFn are formulated by mixing with a mature Protective Antigen (PA).
  • PA Protective Antigen
  • a mature PA also referred to as PA 83 is one wherein there is a cleavage of 29 amino acid residues signal sequence from the native PA. In this state, the PA is inactive except for its binding affinity for a receptor. Only after the furin-mediated cleavage to form PA 63 , the binding of one of the other toxin components is possible. Heptamerization and pore formation after acidification leads to a structure similar to the staphylococcal alpha-hemolysin.
  • the anthrax recombinant fusion proteins comprising EFn and LFn are formulated by mixing with a mutated Protective Antigen.
  • a mutated PA also prevents the binding of the Edema factor protein or Lethal factor protein and thus might avoid the formation of Edema Toxin or Lethal Toxin respectively leading to better product safety.
  • the composition of the present invention comprising anthrax recombinant fusion proteins is capable of producing at least one or more of the anti-PA, anti-LF and anti-EF antibodies that shall work as neutralizing antibodies and, therefore, shall interrupt binding activities of the anthrax toxin. Therefore, the present invention, by using EFn, LFn and native or mature or mutated PA as antigens, may result in faster immune responses by targeting all three toxin proteins namely PA, EF and LF, since the presence of different antibodies allows attack of different proteins at the same time.
  • anthrax recombinant fusion proteins comprising EFn and LFn optionally with a linker, mixed with a native or mature or mutated PA is provided to target all three proteins i.e., PA, LF, and EF.
  • the linker molecule facilitates the independent folding of the EFn and LFn proteins of the fusion construct. This helps in imparting better immunogenic response of the EFn and LFn proteins.
  • Many of the antibodies raised against EF or LF may neutralize the toxic effect of the anthrax toxin by interrupting the binding of EF and/or LF and PA.
  • the present invention provides anthrax recombinant fusion proteins comprising a native or mutated or truncated EF protein and a native or mutated or truncated LF protein optionally with one or more linkers inserted at one or more sites of the fusion protein chain.
  • the linker is one or more amino acids such as glycine or amino acid residue.
  • the linker is also herein referred to as a spacer peptide.
  • the linker is preferably selected from one or more amino acids, amino acid residues, glycine, polyglycine, and others thereof.
  • the present invention provides an anthrax recombinant fusion protein comprising truncated Edema factor protein (SEQ. ID No. 2) and truncated lethal factor protein (SEQ. ID No. 1) optionally with a linker.
  • the present invention provides an anthrax recombinant fusion protein comprising truncated Edema factor protein (SEQ. ID No. 2) and and truncated lethal factor protein (SEQ. ID No. 1) optionally with linker wherein linker is amino acid or amino acid residue such as glycine.
  • the present invention provides an immunogenic composition
  • anthrax recombinant fusion protein comprising truncated Edema factor protein (SEQ. ID No. 2) and truncated lethal factor protein (SEQ. ID No. 1) optionally with a linker.
  • the present invention provides an immunogenic composition
  • anthrax recombinant fusion protein comprising truncated Edema factor protein (SEQ. ID No. 2) and truncated lethal factor protein (SEQ. ID No. 1) optionally with a linker wherein linker is amino acid or amino acid residue such as glycine.
  • the present invention provides an immunogenic composition
  • anthrax recombinant fusion protein comprising truncated Edema factor protein (SEQ. ID No. 2) and truncated lethal factor protein (SEQ. ID No. 1) optionally with a linker; and protective antigen.
  • the present invention provides an immunogenic composition comprising anthrax recombinant fusion protein (SEQ. ID. No. 3).
  • the present invention provides an immunogenic composition comprising anthrax recombinant fusion protein (SEQ. ID. No. 4).
  • the present invention provides anthrax recombinant fusion proteins that ease the vaccine production by reducing the need for separate production lines for fermentation and purification procedures for each protein i.e. EFn and LFn individually.
  • the said fusion protein can further be mixed with other antigens such as a native or mature or mutated PA.
  • At least two antigenic B. anthracis proteins are over-expressed as a fusion protein, in an E. coli host cell such as the BL- 21(DE3) (from Novagen).
  • the over-expressed proteins are produced by an optimized fermentation method and purified by one or more techniques known to the art such as column chromatography.
  • the purified proteins are useful in formulating an immunogenic composition, which is again useful as a vaccine against infections caused by B. anthracis.
  • Development of an E. coli BL-21(DE3) over-expression system involves the development of expression vector (plasmids) to express the target recombinant fusion proteins in an E. coli BL-21(DE3). It might however be understood that alternative vectors/plasmids and/or expression host might be utilized for the production of the novel fusion proteins of the present invention such as the use of Bacillus subtilis as the host cell for the fusion protein expression.
  • the expression vector described herein is for use in a prokaryotic system; the vector also can contain elements required for replication in either a prokaryotic or eukaryotic host system or both, as desired.
  • vectors which include plasmid vectors and viral vectors such as bacteriophage, baculovirus, retrovirus, lentivirus, adenovirus, vaccinia virus, semliki forest virus and adeno-associated virus vectors, are well known and can be purchased from a commercial source (Promega, Madison Wis.; Stratagene, La Jolla Calif.; GIBCO/BRL, Gaithersburg Md.) or can be constructed by one skilled in the art.
  • Bacterial pQE70, pQE30, pET28a (Qiagen), pBluescript SK, pBluescript KS (Stratagene); pTRC99a, pRlT2T (Pharmacia); Eukaryotic: pWLNEO, pXTI, pSG (Stratagene) pSVK3, pSVLSV40 (Pharmacia). Any other plasmid or vector may be used as long as they are replicable and viable in the host being used to express the fusion proteins of the present invention.
  • the process for preparation of an anthrax recombinant fusion protein comprises the following steps: a. Development of a suitable DNA construct comprising a vector and DNA fragment encoding for the desired fusion protein, b. Clone development for the production of recombinant fusion protein EFn-LFn or EFn-(Linker)-LFn, c. Expression of the fusion protein in a suitable host, purification and characterization of recombinant fusion protein, d. Obtaining the native or mature or mutated PA, e.
  • the process for preparation of a recombinant protective antigen comprises the following steps: a. Development of a suitable DNA construct comprising a vector and DNA fragment encoding for the PA protein, b. Clone development for production of recombinant protective antigen (rPA), and c. Expression of the recombinant protective antigen (rPA) in a suitable host, purification and characterization of recombinant protective antigen (rPA),
  • the process for preparation of an anthrax recombinant fusion protein comprises the following steps: a. Amplification of the EFn and LFn gene from the genomic DNA of Bacillus anthracis using specific primers optionally having glycine residues as a linker, b. Insertion of fusion protein of EFn and LFn proteins in the expression vector, c. Restriction digestion of the gene and vector, d. Ligation and transformation into competent E. coli DH5 ⁇ cells, e. Selecting the transformants on LB agar containing an antibiotic such as kanamycin, f. Screening of the colonies on the agar plates by colony PCR for the presence of the desired gene, g. Confirming the selected clone by digestion with restriction enzymes, and h. Transforming the recombinant plasmid into host cells for the expression of the fusion protein.
  • the process for preparation of an anthrax recombinant protective antigen comprises the following steps: a. Amplification of the PA gene from the genomic DNA of Bacillus anthracis using specific primers optionally having glycine residues as a linker, b. Insertion of PA proteins in the expression vector, c. Restriction digestion of the gene and vector, d. Ligation and transformation into competent E. coli DH5 ⁇ cells, e. Selecting the transformants on LB agar containing an antibiotic such as kanamycin, f. Screening of the colonies on the agar plates by colony PCR for presence of the desired gene, g. Confirming the selected clone by digestion with restriction enzymes, and h. Transforming the recombinant plasmid into host cells for expression of PA.
  • the process for preparation of an anthrax recombinant fusion protein comprises the following steps: a. Amplification of EFn with LFn (as tail) gene from the genomic DNA of Bacillus anthracis using specific primers optionally having glycine residues as a linker, b. Insertion of EFn with LFn as tail protein in the expression vector, c. Restriction digestion of the gene and vector, d. Ligation and transformation into competent E. coli DH5 ⁇ cells, e. Selecting the transformants on LB agar containing an antibiotic such as kanamycin, f. Screening of the colonies on the agar plates by colony PCR for the presence of the desired gene, g. Confirming the selected clone by digestion with restriction enzymes, h. Transforming the recombinant plasmid into host cells for the expression of the fusion protein, and i. Fermentation and purification of EFn+LFn protein.
  • the EFn+LFn protein thus obtained may be mixed with anthrax recombinant native or mature or mutated PA and made into a composition along with one or more suitable adjuvant(s).
  • the method used for the preparation of fusion proteins is selected from one of more methods known to the art.
  • the upstream process for an anthrax recombinant fusion protein production may be carried out by a batch process or preferably by using fed-batch culture technique to improve the yield of the fusion protein.
  • the optimization of various fermentation parameters using fed-batch conditions shall improve protein yields and stability. Standardization of fermentation parameters shall require systematic design of experiments as follows: a) Different nitrogen source such as Soya peptone, yeast extract, yeast autolysate, corn steep liquor or the like or mixtures thereof in the fermentation media. b) Different carbon sources such as glucose, glycerol, galactose, maltose, fructose, lactose or the like or mixtures thereof in the fermentation media.
  • the fermentation media used in the present invention is devoid of any component obtained from an animal source.
  • the downstream purification process of the recombinant fusion proteins is based upon their localization in the cell as inclusion bodies, periplasmic fluid or extracellular secretions. Based on the nature of protein localization and its isoelectric point (PI), various chromatographic methods may be used such as anion exchange chromatography, hydrophobic interaction chromatography and size exclusion or gel filtration chromatography, difiltration or the like, or combinations thereof.
  • PI isoelectric point
  • anthrax recombinant fusion proteins shall work as neutralizing antibodies and, therefore, will interrupt binding activities of the anthrax toxin.
  • PA is a 735-amino acid polypeptide of about 83 kDa that binds to the surface of mammalian cells by cellular receptors. Once bound, PA is activated by proteolytic cleavage by cellular proteases to a 63-kDa and 20-kDa molecule.
  • 63-kDa molecule is capable of forming a ring-shaped heptamer in the plasma membrane of the targeted cell exposing PA binding sites for the N-terminal region of either LF or EF which are then internalized by endocytosis.
  • the complex is then carried to an acidic compartment, where the low pH causes a conformational change in the PA63 pre-pore that forms a cation-specific channel and allows the EF and LF to enter into the cytosol. This process is known as endosomal acidification.
  • the EF and LF then carry out their respective damage -inducing processes.
  • EF acts as a Ca2+ and calmodulin dependent adenylate cyclase that greatly increases the level of cAMP in the cell. This increase in cAMP upsets water homeostasis, severely throws the intracellular signaling pathways off balance, and impairs macrophage function, allowing the bacteria to further evade the immune system. LF also helps the bacteria evade the immune system through killing macrophages. Once in these cells, LF acts as a Zn 2+ -dependent endoprotease that snips off the N-terminus of mitogen-activated protein kinase kinases (MAPKK).
  • MAPKK mitogen-activated protein kinase kinases
  • PA is the major immunogen in the anthrax vaccines.
  • Antibodies to PA neutralize anthrax toxin by blocking adherence of PA to host cells, binding of LF/EF to PA, or assembly of PA heptamer.
  • LF represents both a prophylactic and therapeutic target because it has been reported to play a vital role at two different points in anthrax infection. It elicits humoral and cell-mediated immune response and memory.
  • the vaccine may be administered by conventional routes, e.g. intravenous, subcutaneous, intraperitoneal and mucosal routes.
  • the said vaccine can be administered through jet injection with needle or without needle.
  • such vaccines are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared.
  • the preparation may also be emulsified, or the peptide encapsulated in liposomes or microcapsules.
  • the active immunogenic ingredients are often mixed with excipients which are pharmaceutically acceptable and compatible with the active components. Suitable excipients are for example, water, saline, dextrose, glycerol, ethanol, sugars or the like and combinations or derivatives thereof.
  • the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine.
  • adjuvants which may be effective include but are not limited to aluminum hydroxide, aluminium phosphate, calcium phosphate, immunostimulatory sequence (ISS), CpG, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP),, N-acetyl-nor- muramyl-L-alanyl-D-isoglutamine (CGP 1 1637, referred to as nor-MDP), N- acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine ( 1 '-2'-dipalmitoyl-sn-glycero hydroxylphosphoryloxy) ethylamine (CGP 19835A, referred to as MTP-PE),
  • the vaccines of the present invention may be conventionally administered parenterally by injection, for example, either subcutaneously or intramuscularly.
  • the said vaccine can be administered through jet injection with needle or without needle.
  • the vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be prophylactically and/or therapeutically effective.
  • the quantity to be administered which is generally in the range of 0.5 micrograms to 500 micrograms of protein per dose, depends on the subject to be treated, capacity of the subject's immune system to synthesize antibodies, and the degree of protection desired. Precise amounts of active ingredient required to be administered may depend on the judgment of the practitioner and may be particular to each subject.
  • the vaccine may be given in a single dose schedule, or optionally in a multiple dose schedule.
  • a multiple dose schedule is one in which, a primary course of vaccination may be with 1-12, preferably 1-6 separate doses, followed by other doses given at subsequent time intervals required to maintain and/or reinforce the immune response, for example, at 1- 4 months for a second dose, and if needed, a subsequent dose(s) after several months.
  • the dosage regimen will also at least in part be determined by the need of the individual and be dependent upon the judgment of the practitioner.
  • the vaccine containing the immunogenic antigen(s) may be administered in conjunction with other immunoregulatory agents, for example, immunoglobulins, as well as antibiotics.
  • Additional formulations which are suitable for other modes of administration include microcapsules, suppositories and, in some cases, oral formulations or formulations suitable for distribution as aerosols.
  • traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5 % to 10 %, preferably 1-2%.
  • Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10-95% of active ingredient, preferably 25-70%.
  • the medicament may be administered intranasally (i.n.).
  • An intranasal composition may be administered in droplet form having approximate diameters in the range of 10-5000 pm. Intranasal administration may be achieved by way of applying nasal droplets or via a nasal spray. It is possible that, following i.n. delivery of antibodies, their passage to the lungs may facilitated by a reverse flow of mucosal secretions.
  • the medicament may be delivered in an aerosol formulation.
  • the aerosol formulation may take the form of a powder, suspension or solution.
  • the size of aerosol particles is one factor relevant to the delivery capability of an aerosol. Thus, smaller particles may travel further down the respiratory airway towards the alveoli than would larger particles.
  • the aerosol particles have a diameter distribution to facilitate delivery along the entire length of the bronchi, bronchioles, and alveoli.
  • the particle size distribution may be selected to target an articular section of the respiratory airway, for example the alveoli.
  • the aerosol particles may be delivered by way of a nebulizer or nasal spray.
  • the particles may have diameters in the approximate range of 0-50 pm, preferably 1-5 pm.
  • the aerosol formulation of the medicament of the present invention may optionally contain a propellant and/or surfactant.
  • a propellant and/or surfactant By controlling size of droplets which are to be administered to a subject to within the defined range of the present invention, it is possible to avoid/minimise inadvertent antigen delivery to the alveoli and thus avoid alveoli associated pathological problems such as inflammation and fibrotic scarring of the lungs.
  • the composition may be delivered as a transdermal formulation e.g. skin delivery patches.
  • a method to produce an immunogenic pre-exposure and post exposure prophylactic or therapeutic response against an infection of B Anthracis in a subject which comprises administration of an effective amount of anthrax recombinant fusion proteins comprising EFn protein, LFn and a linker which is a one or more amino acid residues, mixed with a native or mature or mutated PA and optionally one or more adjuvant(s) to the said subject.
  • a subject is a mammal, particularly domesticated livestock and animals including but not limited to dogs, cats, cows, bulls, steers, pigs, horses, sheep, goats, mules, donkeys, etc.
  • the subject is a human.
  • a subject can be of any age at which the subject is able to respond to inoculation with the present vaccine by generating an immune response.
  • the immune response so generated can be completely or partially protective against disease, cellular toxicity, debilitation or death caused by infection with B. anthracis.
  • a subject is also one to which a composition comprising the fusion protein of the present invention can be administered prophylactically and/or therapeutically.
  • Example-1 Clone development and production of recombinant PA Protective antigen (PA) gene has been codon optimized and synthesized for protein product expression in E.coli.
  • Commercial vector pET 26b (+) were used to express PA gene. After restriction digestion of the gene and vector, both were ligated and transformed into TOPlO ⁇ E.coli) competent cells. The transformants were plated on LB agar containing 50 ⁇ g/ml kanamycin. The colonies on the plates were screened by colony PCR for the presence of the desired gene. The selected clone was confirmed by restriction mapping and sequencing. The recombinant construct was then transformed into E.coli BL21 (DE3) cells for the expression of protein.
  • Below fig-1 illustrate the schematic representation of expression system. The expressed protein was confirmed for its size on SDS-PAGE gel and also by western blotting using Anti-PA monoclonal antibody available from US Biologicals.
  • Recombinant fusion construct EFn-LFn was developed using EFn and LFn gene amplified from cya and lef gene of pXOl plasmid of Bacillus anthracis respectively, using specific primers having glycine residues as spacer peptide inserted in pET-28a expression vector which has Kanamycin as selection marker. The recombinant plasmid was then transformed into E.coli BL21 (DE3) cells for the expression of fusion protein.
  • Example 3 The recombinant PA and the EFn+LFn fusion protein are mixed together optionally with one or more suitable adjuvant(s).
  • E. coli -cell bank preparation was carried out in animal component free medium (ACFM).
  • ACFM animal component free medium
  • PB08 BL21 (DE3)/pPAK
  • kanamycin single colony was grown in liquid ACFM medium for pre-cell bank preparation.
  • OD 6O o spectrophotometer
  • the upstream process for an anthrax recombinant protective protein production was carried out by moderate cell density culture to improve the yield of the recombinant protein.
  • the fermentation media used in the present invention is devoid of any component obtained from an animal source.
  • the culture was harvested in a sterilize bottle & Centrifuged at 5000 rpm for 30 minutes at 5 ⁇ 3 0 C ,the supernatant was discarded & the pellet was stored at minus 20 0 C in polypropylene bottles for future use.
  • the purification of recombinant protective antigen comprises of the following strategy:
  • the pellet obtained was resuspended in lysis buffer in a ratio (1 :10).
  • the lysis was performed using High pressure Homogenizer at 20000-25000psi in two passages and carried centrifugation at 10,000g for 30 min. at 4 0 C.
  • the pellet was washed for Inclusion bodies using washing buffer for 30 min. at 4 0 C and centrifuged at 10,000g for 30 min. at 4 0 C.
  • the efficacy of this process was checked by running on SDS - PAGE & Western blot.
  • the column packed with the resin was firstly equilibrated with start buffer i.e. Buffer-A. After equilibration, 100ml of urea solubilized, clarified and 0.45 ⁇ m filtered sample was loaded. 2CV of Buffer A was passed through column to collect unbound sample. Refolding on column of sample protein was takes place by passing linear gradients of Buffer-A & B (from 100 % A to 100 % B ) extend further for 2 column volumes with Buffer- B followed by 0.5 CV of Buffer -C. The bound rPA was eluted with gradients of Buffer-D. The peak fractions thus collected was analysed for their concentration & purity with SDS-PAGE (Coomassie brilliant Blue + silver staining) & Western blot. The column was regenerated by 5 CV of Buffer E.
  • the purified protein collected after Macroprep Q was subjected to hydroxyapatitte chromatography. Mannitol ( @1% -10%) & Tween -80 ( @ 0.2% -2%) were added to the final purified protein obtained after hydroxyapatite chromatography. The final purified protein with additives were subjected to sterile filtration. The active raw material was tested by different analytical & bioanalytical tests (Reverse phase high- pressure liquid chromatography, Macrophage lysis assay, Host cell protein, host cell DNA, Endotoxin, Circular Dichromism etc.)
  • immunogenic composition of anthrax recombinant fusion proteins of the present invention can prepared by following process:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des protéines hybrides recombinées du charbon, des procédés destinés à la préparation de ces protéines et des compositions contenant ces protéines. Plus précisément, les protéines hybrides recombinées de la présente invention comprennent la protéine du facteur oedème (EF), de préférence une protéine du facteur oedème (EF) native ou une protéine du facteur oedème (EFm) mutée ou une protéine du facteur oedème (EFn) tronquée ou, mieux encore, une protéine du facteur oedème (EFn) tronquée et la protéine du facteur létal (LF), de préférence une protéine du facteur létal (LF) native ou une protéine du facteur létal (LFm) mutée ou une protéine du facteur létal (LFn) tronquée ou, mieux encore, une protéine du facteur létal (LFn) tronquée, éventuellement avec un lieur. L'invention concerne également des acides nucléiques codant pour les protéines hybrides de la présente invention. La présente invention concerne également une composition contre une infection par B. anthracis, comprenant la protéine hybride recombinée du charbon mélangée à un antigène protecteur (PA) natif ou adulte ou muté, et éventuellement à un ou plusieurs adjuvants, pouvant être utile comme vaccin thérapeutique et/ou préventif contre le charbon, avant ou après une exposition à la bactérie.
PCT/IN2008/000368 2007-06-11 2008-06-11 Protéines hybrides du charbon, compositions et leurs applications WO2008152654A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1251/DEL/2007 2007-06-11
IN1251DE2007 2007-06-11

Publications (1)

Publication Number Publication Date
WO2008152654A1 true WO2008152654A1 (fr) 2008-12-18

Family

ID=40129293

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000368 WO2008152654A1 (fr) 2007-06-11 2008-06-11 Protéines hybrides du charbon, compositions et leurs applications

Country Status (1)

Country Link
WO (1) WO2008152654A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103520717A (zh) * 2013-09-02 2014-01-22 中山大学 丙氨酸作为疫苗佐剂的应用
US9616117B2 (en) 2008-10-02 2017-04-11 Pharmathene, Inc. Anthrax vaccine formulation and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048390A1 (fr) * 2001-12-05 2003-06-12 Rakesh Bhatnagar Procede de preparation d'un vaccin non toxique contre l'anthrax
US20040028695A1 (en) * 2002-04-12 2004-02-12 Sukjoon Park Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis
WO2008048344A2 (fr) * 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Antigènes de bacillus anthracis, compositions pour vaccins et procédés connexes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048390A1 (fr) * 2001-12-05 2003-06-12 Rakesh Bhatnagar Procede de preparation d'un vaccin non toxique contre l'anthrax
US20040028695A1 (en) * 2002-04-12 2004-02-12 Sukjoon Park Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis
WO2008048344A2 (fr) * 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Antigènes de bacillus anthracis, compositions pour vaccins et procédés connexes

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9616117B2 (en) 2008-10-02 2017-04-11 Pharmathene, Inc. Anthrax vaccine formulation and uses thereof
CN103520717A (zh) * 2013-09-02 2014-01-22 中山大学 丙氨酸作为疫苗佐剂的应用
CN103520717B (zh) * 2013-09-02 2015-11-18 中山大学 丙氨酸作为疫苗佐剂的应用

Similar Documents

Publication Publication Date Title
McBride et al. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers
EP1962890B1 (fr) Composition immunogene
JP2009515831A (ja) ペスト菌（Ｙｅｒｓｉｎｉａｐｅｓｔｉｓ）抗原を含む組成物
JP6084631B2 (ja) Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ毒素ベースのワクチン
JP2012501959A (ja) Ｙｅｒｓｉｎｉａｐｅｓｔｉｓ抗原を含む組成物
US20020197272A1 (en) Methods for protecting against lethal infection with bacillus anthracis
JP4091112B2 (ja) リポタンパク質の発現
US7947268B2 (en) Salmonella based oral vaccines for anthrax
US7355027B2 (en) Bacillus anthracis protective antigen
US20050112145A1 (en) Anthrax antigenic compositions
MX2015002485A (es) Polipeptidos de clostridium difficile como vacuna.
JP2012510289A (ja) グルタミルｔＲＮＡ合成酵素（ＧｔＳ）フラグメント
KR101130884B1 (ko) 패혈증 비브리오균의 플라젤린과 병원체의 항원 단백질을 융합시켜 제조한 재조합 융합 단백질 및 이를 유효성분으로 포함하는 점막 투여용 백신
WO2008152654A1 (fr) Protéines hybrides du charbon, compositions et leurs applications
JP2019531100A (ja) ワクチン構築物およびブドウ球菌感染症に対するその使用
WO2008152655A1 (fr) Protéines hybrides du charbon, compositions et leurs applications
US8323927B2 (en) Preparation of protective antigen
US20130149330A1 (en) Pharmaceutical compositions and methods of blocking bacillus anthracis
WO2020078420A1 (fr) Préparations immunogènes et procédés contre une infection par clostridium difficile
KR102100503B1 (ko) 개선된 고스트 장관독소형 대장균를 유효성분으로 포함하는 돼지 대장균증의 예방 또는 치료용 백신 조성물
US9233150B2 (en) Combination vaccine
US10293040B1 (en) Pharmaceutical compositions and methods of blocking Bacillus anthracis
Jauro Evaluation of veterinary non-living anthrax vaccine candidates in cattle
US20150050312A1 (en) Bacterial vaccine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08763753

Country of ref document: EP

Kind code of ref document: A1

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08763753

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载